Piper Sandler raised the firm’s price target on Travere Therapeutics (TVTX) to $22 from $12 driven by pipeline developments. The firm keeps a Neutral rating on the shares following quarterly results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics 7.81M share Spot Secondary priced at $16.00
- Travere Therapeutics announces common stock offering, no amount given
- Travere Therapeutics price target raised to $27 from $23 at Scotiabank
- Travere Therapeutics price target raised to $20 from $18 at Barclays
- Travere Therapeutics Boosts Sales with FILSPARI Approval
Questions or Comments about the article? Write to editor@tipranks.com